The FDA widened the labeled indication for Rhythm Pharmaceuticals’ Imcivree to include adults and children aged four and older with acquired hypothalamic obesity. The regulator’s approval follows company submissions and additional efficacy analyses requested during review. In clinical testing, Imcivree produced roughly an 18 percentage‑point greater weight‑loss response versus placebo in the target population. Rhythm framed the decision as a major market and patient‑access milestone, estimating a multi‑hundred‑million to >$1 billion opportunity depending on diagnosis rates and uptake. The expansion gives Rhythm a commercial catalyst and illustrates regulator willingness to approve targeted therapies for rare, biologically defined forms of obesity distinct from broad anti‑obesity pharmacology.